Galanin (1-15) (porcine, rat)Galanin receptor agonist peptide CAS# 112747-70-3 |
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
- Flumazenil
Catalog No.:BCC1259
CAS No.:78755-81-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 112747-70-3 | SDF | Download SDF |
| PubChem ID | 16131409 | Appearance | Powder |
| Formula | C72H105N19O20 | M.Wt | 1556.74 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 1 mg/ml in water | ||
| Sequence | GWTLNSAGYLLGPHA | ||
| Chemical Name | (2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoic acid | ||
| SMILES | CC(C)CC(C(=O)NC(CC(C)C)C(=O)NCC(=O)N1CCCC1C(=O)NC(CC2=CN=CN2)C(=O)NC(C)C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)CNC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)CN | ||
| Standard InChIKey | LOXLDVDBPRBBLT-GDRYISODSA-N | ||
| Standard InChI | InChI=1S/C72H105N19O20/c1-35(2)21-47(62(100)78-32-59(98)91-20-12-15-55(91)70(108)87-52(26-43-30-75-34-79-43)63(101)81-39(8)72(110)111)84-64(102)48(22-36(3)4)85-66(104)50(24-41-16-18-44(94)19-17-41)83-58(97)31-77-61(99)38(7)80-69(107)54(33-92)89-67(105)53(27-56(74)95)86-65(103)49(23-37(5)6)88-71(109)60(40(9)93)90-68(106)51(82-57(96)28-73)25-42-29-76-46-14-11-10-13-45(42)46/h10-11,13-14,16-19,29-30,34-40,47-55,60,76,92-94H,12,15,20-28,31-33,73H2,1-9H3,(H2,74,95)(H,75,79)(H,77,99)(H,78,100)(H,80,107)(H,81,101)(H,82,96)(H,83,97)(H,84,102)(H,85,104)(H,86,103)(H,87,108)(H,88,109)(H,89,105)(H,90,106)(H,110,111)/t38-,39-,40+,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | N-terminal galanin fragment. In contrast to the full length (1-29) peptide, mediates central cardiovascular effects, perhaps by binding to a novel receptor type. |
Galanin (1-15) (porcine, rat) Dilution Calculator
Galanin (1-15) (porcine, rat) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- exo-IWR 1
Catalog No.:BCC7823
CAS No.:1127442-87-8
- IWR-1-endo
Catalog No.:BCC5102
CAS No.:1127442-82-3
- Oleonuezhenide
Catalog No.:BCN6011
CAS No.:112693-21-7
- Erigeside C
Catalog No.:BCN6010
CAS No.:112667-09-1
- Fragransin A2
Catalog No.:BCN6008
CAS No.:112652-46-7
- 1,7-Dihydroxyacridone
Catalog No.:BCN7275
CAS No.:112649-95-3
- BR-Xanthone A
Catalog No.:BCN6007
CAS No.:112649-48-6
- Garcinone E
Catalog No.:BCN3604
CAS No.:112649-21-5
- U-73122
Catalog No.:BCC5199
CAS No.:112648-68-7
- Dicyclanil
Catalog No.:BCC8938
CAS No.:112636-83-6
- Iso-mogroside V
Catalog No.:BCN3047
CAS No.:1126032-65-2
- 4-Allylpyrocatechol
Catalog No.:BCN6009
CAS No.:1126-61-0
- Clemastanin B
Catalog No.:BCC8152
CAS No.:112747-98-5
- Osthenone
Catalog No.:BCN4731
CAS No.:112789-90-9
- Letrozole
Catalog No.:BCC1063
CAS No.:112809-51-5
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester
Catalog No.:BCC8465
CAS No.:112811-71-9
- 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
Catalog No.:BCC8464
CAS No.:112811-72-0
- Dynole 34-2
Catalog No.:BCC7891
CAS No.:1128165-88-7
- Methyllycaconitine citrate
Catalog No.:BCC6897
CAS No.:112825-05-5
- 24R-Calcipotriol
Catalog No.:BCC1304
CAS No.:112827-99-3
- (24R)-MC 976
Catalog No.:BCC1289
CAS No.:112828-09-8
- (24S)-MC 976
Catalog No.:BCC1291
CAS No.:112849-14-6
- Fmoc-D-Met-OH
Catalog No.:BCC3532
CAS No.:112883-40-6
The galanin receptor antagonist M40 blocks the central cardiovascular actions of the galanin N-terminal fragment (1-15).[Pubmed:10884520]
Eur J Pharmacol. 2000 Jul 7;399(2-3):197-203.
It has been shown that galanin plays a role in central cardiovascular regulation. Galanin administered centrally induces an increase of heart rate and a weak vasodepressor response, whereas the N-terminal galanin fragment (1-15) elicits vasopressor effects and tachycardia. Furthermore, it has been shown that galanin-(1-15), but not galanin-(1-29), decreases the baroreceptor reflex sensitivity. Since these data demonstrate that both galanin and its N-terminal fragment (1-15) exert a different modulation on central cardiovascular control, the aim of this work has been to study if the specific galanin receptor antagonist Galanin-(1-12)-Pro-(Ala-Leu)(2)-Ala]-amide (M40) could modulate their cardiovascular actions. Urethane anaesthetized rats were injected intracisternally and the changes in mean arterial pressure and heart rate were monitored. Two doses of M40 alone have been tested for their cardiovascular effects. With the dose of 1.0 nmol, a significant tachycardia was observed (P<0.001), but 0.1 nmol was ineffective. This suggests a possible agonistic effect for the higher doses of M40. The galanin receptor antagonist M40 at the dose of 0.1 nmol failed to modify the weak vasodepressor effects and tachycardia induced by 3.0 nmol of galanin-(1-29). However, the same dose completely blocked the vasopressor and tachycardic responses elicited by 3.0 nmol of galanin-(1-15). These data show that M40 differentially counteracts the central cardiovascular responses of the galanin fragment and give a functional support for the existence of galanin receptor subtypes within the brainstem. Therefore, the present findings can be explained on the basis that the cardiovascular actions of galanin-(1-29) could be mediated by one type of galanin receptor, whereas a galanin receptor subtype that recognizes N-terminal fragments of galanin may mediate the actions of galanin-(1-15).
Electrophysiological evidence for a hyperpolarizing, galanin (1-15)-selective receptor on hippocampal CA3 pyramidal neurons.[Pubmed:10588748]
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14583-7.
The effects of the 29-amino acid neuropeptide galanin [GAL (1-29)], GAL(1-15), GAL(1-16), and the GAL subtype 2 receptor agonist D-tryptophan(2)-GAL(1-29) were studied in the dorsal hippocampus in vitro with intracellular recording techniques. GAL(1-15) induced, in the presence of tetrodotoxin, a dose-dependent hyperpolarization in hippocampal CA3 neurons. Most of the GAL(1-15)-sensitive neurons did not respond to GAL(1-29), GAL(1-16), or D-tryptophan(2)-GAL(1-29). These results indicate the presence of a distinct, yet-to-be cloned GAL(1-15)-selective receptor on CA3 neurons in the dorsal hippocampus.
Structural requirement for galanin action in the pancreatic beta cell line Rin m 5F.[Pubmed:2472967]
Eur J Pharmacol. 1989 Apr 12;163(1):205-7.
Galanin fragments were tested for their ability to alter forskolin-stimulated cyclic AMP production and insulin release from Rin m 5F cells. Galanin and its fragments inhibited both events with the following potencies: Gal-(1-29) greater than N-AcGal-(2-29) greater than Gal-(2-29) greater than Gal-(1-15). In contrast, Gal-(3-29), Gal-(10-29) and [Ile2]Gal were inactive. [Phe2]- and [Tyr2]Gal were moderately effective. We conclude that the N-terminal portion of galanin (in particular the aromatic amino acid in position 2) is crucial for activity.
